317 related articles for article (PubMed ID: 28676199)
1. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study.
Pipa-Muñiz M; Castells L; Pascual S; Fernández-Castroagudín J; Díez-Miranda I; Irurzun J; Díaz-Beveridge R; Senosiaín M; Arenas J; de la Mata M; Turnes J; Monge-Romero MI; Pérez-Enguix D; Bustamante-Schneider J; Otegui N; Molina-Pérez E; Rodríguez-Menéndez JE; Varela M
Gastroenterol Hepatol; 2017 Oct; 40(8):515-524. PubMed ID: 28676199
[TBL] [Abstract][Full Text] [Related]
2. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization.
Sánchez-Delgado J; Vergara M; Machlab S; Lira A; Gómez Zaragoza C; Criado E; Rosinach M; Batista L; Arau B; Roget M; Ortiz J; Garcia C; Sort P; Casas M; Dalmau B; Forné M; Falcó J; Miquel M
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1453-1460. PubMed ID: 30113926
[TBL] [Abstract][Full Text] [Related]
3. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series.
Terzi E; Terenzi L; Venerandi L; Croci L; Renzulli M; Mosconi C; Allegretti G; Granito A; Golfieri R; Bolondi L; Piscaglia F
Dig Dis; 2014; 32(6):711-6. PubMed ID: 25376288
[TBL] [Abstract][Full Text] [Related]
4. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.
Hucke F; Pinter M; Graziadei I; Bota S; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M; Sieghart W
J Hepatol; 2014 Dec; 61(6):1287-96. PubMed ID: 25016222
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
[TBL] [Abstract][Full Text] [Related]
6. Survival in unresectable AJCC stage I and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study.
Xing M; Kokabi N; Prajapati HJ; Close O; Ludwig JM; Kim HS
J Comp Eff Res; 2016 Mar; 5(2):141-54. PubMed ID: 26946950
[TBL] [Abstract][Full Text] [Related]
7. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
9. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma.
Sieghart W; Hucke F; Pinter M; Graziadei I; Vogel W; Müller C; Heinzl H; Trauner M; Peck-Radosavljevic M
Hepatology; 2013 Jun; 57(6):2261-73. PubMed ID: 23316013
[TBL] [Abstract][Full Text] [Related]
10. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.
Chen L; Ni CF; Chen SX; Cao JM; Zhu HD; Guo JH; Zhu GY; Zhong BY; Ding W; He SC; Deng G; Teng GJ
J Vasc Interv Radiol; 2016 Sep; 27(9):1288-1297. PubMed ID: 27013402
[TBL] [Abstract][Full Text] [Related]
11. The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization.
Pipa-Muñiz M; Sanmartino S; Mesa A; Álvarez-Navascués C; González-Diéguez ML; Cadahía V; Rodríguez JE; Vega F; Rodríguez M; Costilla-García SM; Varela M
BMC Gastroenterol; 2020 Jun; 20(1):166. PubMed ID: 32487071
[TBL] [Abstract][Full Text] [Related]
12. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE.
Hucke F; Sieghart W; Pinter M; Graziadei I; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M
J Hepatol; 2014 Jan; 60(1):118-26. PubMed ID: 24012941
[TBL] [Abstract][Full Text] [Related]
13. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma.
Mähringer-Kunz A; Kloeckner R; Pitton MB; Düber C; Schmidtmann I; Galle PR; Koch S; Weinmann A
Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1017-1025. PubMed ID: 28197830
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of ART Scores for Repeated Transarterial Chemoembolization in Japanese Patients with Hepatocellular Carcinoma.
Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Ida H; Minami Y; Sakurai T; Nishida N; Kitano M; Kudo M
Oncology; 2015; 89 Suppl 2():4-10. PubMed ID: 26584030
[TBL] [Abstract][Full Text] [Related]
15. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
[TBL] [Abstract][Full Text] [Related]
17. Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia.
Rahman FA; Naidu J; Ngiu CS; Yaakob Y; Mohamed Z; Othman H; Jarmin R; Elias MH; Hamid NA; Mokhtar NM; Ali RR
Asian Pac J Cancer Prev; 2016; 17(8):4037-41. PubMed ID: 27644658
[TBL] [Abstract][Full Text] [Related]
18. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
Li L; Gou CY; Li JY; Achakzai R; Li XH
Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
[TBL] [Abstract][Full Text] [Related]
20. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
Li H; Wu F; Duan M; Zhang G
Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
